Functional domains of wild-type and mutant p53 proteins involved in transcriptional regulation, transdominant inhibition, and transformation suppression
暂无分享,去创建一个
M. Scheffner | P. Howley | T. Unger | J. Mietz | C. Yee | Peter M. Howley | Carole Yee | Martin Scheffner | Judy A. Mietz | Tamar Unger
[1] J. Sambrook,et al. Molecular Cloning: A Laboratory Manual , 2001 .
[2] C. Finlay,et al. The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth , 1993, Molecular and cellular biology.
[3] P. Howley,et al. The transcriptional transactivation function of wild‐type p53 is inhibited by SV40 large T‐antigen and by HPV‐16 E6 oncoprotein. , 1992, The EMBO journal.
[4] E. Shaulian,et al. Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding , 1992, Molecular and cellular biology.
[5] D. Lane,et al. Regulation of the specific DNA binding function of p53 , 1992, Cell.
[6] B. Vogelstein,et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia , 1992, Cell.
[7] M. Subler,et al. Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells , 1992, Journal of virology.
[8] E. Appella,et al. Growth arrest induced by wild-type p53 protein blocks cells prior to or near the restriction point in late G1 phase. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[9] P. Friedman,et al. Site-specific binding of wild-type p53 to cellular DNA is inhibited by SV40 T antigen and mutant p53. , 1992, Genes & development.
[10] Bert Vogelstein,et al. p53 function and dysfunction , 1992, Cell.
[11] M. Remm,et al. A C-terminal alpha-helix plus basic region motif is the major structural determinant of p53 tetramerization. , 1992, Oncogene.
[12] S. Friend,et al. Germ-line mutations of the p53 tumor suppressor gene in patients with high risk for cancer inactivate the p53 protein. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[13] P. Friedman,et al. Wild-type p53 activates transcription in vitro , 1992, Nature.
[14] P. Meltzer,et al. Amplification of a gene encoding a p53-associated protein in human sarcomas , 1992, Nature.
[15] A. Levine,et al. Wild-type p53 mediates positive regulation of gene expression through a specific DNA sequence element. , 1992, Genes & development.
[16] A. Levine,et al. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation , 1992, Cell.
[17] J. Shay,et al. A transcriptionally active DNA-binding site for human p53 protein complexes , 1992, Molecular and cellular biology.
[18] P. Shaw,et al. Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[19] A. Berk,et al. Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein , 1992, Nature.
[20] R. Iggo,et al. Mammalian p53 can function as a transcription factor in yeast. , 1992, Nucleic acids research.
[21] T. Unger,et al. p53: a transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer. , 1992, The EMBO journal.
[22] K. Kinzler,et al. Definition of a consensus binding site for p53 , 1992, Nature Genetics.
[23] L. Tsai,et al. Independent binding of the retinoblastoma protein and p107 to the transcription factor E2F , 1992, Nature.
[24] G. Lozano,et al. Analysis of p53 mutants for transcriptional activity , 1991, Molecular and cellular biology.
[25] M. Yaniv,et al. Wild-type p53 can down-modulate the activity of various promoters. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[26] V. Rotter,et al. Involvement of wild-type p53 in pre-B-cell differentiation in vitro. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[27] V. Rotter,et al. A DNA binding domain is contained in the C-terminus of wild type p53 protein. , 1991, Nucleic acids research.
[28] U. Santhanam,et al. Repression of the interleukin 6 gene promoter by p53 and the retinoblastoma susceptibility gene product. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[29] A. Kimchi,et al. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6 , 1991, Nature.
[30] B. Vogelstein,et al. p53 mutations in human cancers. , 1991, Science.
[31] K. Kinzler,et al. Identification of p53 as a sequence-specific DNA-binding protein , 1991, Science.
[32] S. Tapscott,et al. The MCK enhancer contains a p53 responsive element. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[33] J. Milner,et al. Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation , 1991, Cell.
[34] W. Blattner,et al. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li–Fraumeni syndrome , 1990, Nature.
[35] C. Dang,et al. A potential transcriptional activation element in the p53 protein. , 1990, Oncogene.
[36] L. Strong,et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. , 1990, Science.
[37] B. Vogelstein,et al. p53 functions as a cell cycle control protein in osteosarcomas , 1990, Molecular and cellular biology.
[38] G. Lozano,et al. Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. , 1990, Science.
[39] S. Fields,et al. Presence of a potent transcription activating sequence in the p53 protein. , 1990, Science.
[40] T. Soussi,et al. Structural aspects of the p53 protein in relation to gene evolution. , 1990, Oncogene.
[41] A. Levine,et al. Association of human papillomavirus types 16 and 18 E6 proteins with p53. , 1990, Science.
[42] J. Minna,et al. p53: a frequent target for genetic abnormalities in lung cancer. , 1989, Science.
[43] T. Soussi,et al. Evolutionary conservation of the biochemical properties of p53: specific interaction of Xenopus laevis p53 with simian virus 40 large T antigen and mammalian heat shock proteins 70 , 1989, Journal of virology.
[44] W. Schaffner,et al. Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells. , 1989, Nucleic acids research.
[45] A. Levine,et al. The p53 proto-oncogene can act as a suppressor of transformation , 1989, Cell.
[46] D. Ledbetter,et al. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. , 1989, Science.
[47] M. Oren,et al. Oligomerization of oncoprotein p53 , 1988, Journal of virology.
[48] J. Nevins,et al. Activation of gene expression by adenovirus and herpesvirus regulatory genes acting in trans and by a cis-acting adenovirus enhancer element , 1983, Cell.
[49] B. Howard,et al. Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells , 1982, Molecular and cellular biology.
[50] A. Levine,et al. Characterization of a 54K Dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells , 1979, Cell.
[51] D. Lane,et al. T antigen is bound to a host protein in SY40-transformed cells , 1979, Nature.
[52] A. van der Eb,et al. A new technique for the assay of infectivity of human adenovirus 5 DNA. , 1973, Virology.
[53] K. Kinzler,et al. Oncogenic forms of p53 inhibit p53-regulated gene expression. , 1992, Science.
[54] J. E. Stenger,et al. Formation of stable p53 homotetramers and multiples of tetramers , 1992, Molecular carcinogenesis.
[55] J. Minna,et al. Temperature-sensitive mutants of p53 associated with human carcinoma of the lung. , 1992, Oncogene.